2/27
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/25
06:00 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
Low
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
2/23
06:00 am
idya
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
Low
Report
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
2/19
07:20 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
2/18
11:37 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $49.00 price target on the stock.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $49.00 price target on the stock.
2/18
11:15 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
2/18
10:42 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $50.00 price target on the stock.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $50.00 price target on the stock.
2/18
08:42 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its price target raised by analysts at Wedbush from $49.00 to $52.00. They now have an "outperform" rating on the stock.
Medium
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its price target raised by analysts at Wedbush from $49.00 to $52.00. They now have an "outperform" rating on the stock.
2/17
06:00 am
idya
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Low
Report
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
2/2
02:31 pm
idya
Has The Market Overreacted To Recent Weakness In IDEAYA Biosciences (IDYA) Shares? [Yahoo! Finance]
Low
Report
Has The Market Overreacted To Recent Weakness In IDEAYA Biosciences (IDYA) Shares? [Yahoo! Finance]
2/2
06:26 am
idya
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events [Yahoo! Finance]
2/2
06:00 am
idya
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
Medium
Report
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
2/2
12:20 am
idya
A Look At IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Pullback [Yahoo! Finance]
Medium
Report
A Look At IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Pullback [Yahoo! Finance]
1/30
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1/24
05:08 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
07:17 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
1/11
01:27 pm
idya
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/11
12:00 pm
idya
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
1/7
10:57 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $50.00 price target on the stock.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $50.00 price target on the stock.
1/6
09:02 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) was given a new $60.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
IDEAYA Biosciences (NASDAQ:IDYA) was given a new $60.00 price target on by analysts at Truist Financial Corporation.
1/5
06:17 am
idya
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/5
06:00 am
idya
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
12/14
07:44 pm
idya
Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial [Yahoo! Finance]
Medium
Report
Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial [Yahoo! Finance]
12/11
06:27 am
idya
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma [Yahoo! Finance]
12/11
06:00 am
idya
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
Low
Report
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma